Article 401: South Africa: An Important Gateway
- Perceived mainly as a good place to conduct HIV trials and rescue trials, South Africa has been working toward projecting a more well-rounded image—that of a country with first-class research infrastructure, an ideal mix of first- and third-world disease patterns and a first-rate regulatory body. Growth of the clinical trials industry in South Africa stems from recent legislative changes, a favorable exchange rate, wider public awareness about clinical trials and the need for doctors to find alternative revenue streams. Underlying it all is the production of consistent quality data. Further growth should result from South Africa’s role as a gateway to the rest of Africa.
Article 402: Proactive Investigators Talking up Recruitment Success
- Patient recruitment is the leading bottleneck in the clinical development process, so more principal investigators are responding to enrollment inefficiencies by becoming proactive and personally recruiting patients. This hands-on approach to patient recruitment may be a successful single-pronged approach for some busy PIs. All sites can benefit from having an active PI as part of a multi-pronged patient recruitment campaign.
Article 403: Portugal Set for Trial Patient Growth
- Implementation of Directive 2001/20/EC has been delayed in Portugal even though the law was passed there last summer.
Article 404: Eye on: Prostate Cancer
- Prostate cancer will result in more than 30,000 deaths in the United States in 2005. CenterWatch has identified a pipeline of 51 drugs in development for prostate cancer.